Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness

Table 3 Association of the transcripts expression levels with clinicopathological features in BC patients

Characteristic	Subgroups	^amiR-182-5p	miR-146a-5p	miR-498	BRCA1	BRCA2	CHEK2	BRIP1	RAD51	BARD1
Age	< 50 (32)	1.08	0.94	0.95	0.52	1.11	0.12	0.36	0.83	1.02
	≥50 (30)	1.18	1.16	0.64	0.45	1.29	0.44	0.39	1.06	1.2
	P.value	0.75	0.79	0.23	0.93	0.47	0.03	0.74	0.9	0.98
Tumor size	< 2 (16)	0.53	0.68	0.39	0.3	0.63	0.77	0.36	0.62	0.84
	2–5 (40)	1.18	1.21	0.77	0.49	1.57	0.24	0.44	1.18	1.57
	> 5 (6)	2.63	1.02	0.74	0.46	0.88	0.12	0.25	0.94	1.04
	P.value	0.02	0.47	0.62	0.54	0.09	0.29	0.7	0.8	0.63
Estrogene receptor	Positive (27)	0.57	0.76	0.81	0.8	1.06	0.5	0.41	1.53	0.76
	Negative (35)	1.62	1.41	0.68	0.48	1.32	0.14	0.35	0.86	1.54
	P.value	0.0008	0.008	0.95	0.86	0.36	0.04	0.57	0.03	0.19
Progesterone receptor	Positive (25)	0.59	0.67	0.81	0.5	0.9	0.39	0.37	1.06	0.56
	Negative (37)	1.36	1.56	0.66	0.48	1.53	0.17	0.39	0.97	1.54
	P.value	0.007	0.001	0.53	0.87	0.15	0.25	0.44	0.03	0.69
HER2	Positive (27)	0.67	0.79	0.81	0.53	1.06	0.39	0.4	1.16	0.76
	Negative (35)	1.49	1.41	0.66	0.42	1.32	0.17	0.35	0.9	1.54
	P.value	0.02	0.03	0.66	0.54	0.45	0.34	0.73	0.03	0.75
Lymph nodes metastasis	Yes (28)	1.42	1.21	0.85	0.58	1.21	0.12	0.29	1.1	1.05
	No (34)	0.63	0.98	0.57	0.34	1.11	0.29	0.49	0.85	1.09
	P.value	0.008	0.41	0.03	0.31	0.65	0.09	0.1	0.04	0.9
Histologic grade	G1 (10)	0.29	0.29	0.21	0.17	0.38	0.54	0.25	0.6	0.72
	G2 (33)	1.04	1.29	0.81	0.48	1.06	0.28	0.49	1.16	1.11
	G3 (19)	2	1.56	0.68	0.55	1.62	0.12	0.35	0.9	1.44
	P.value	0.01	0.06	0.15	0.06	0.28	0.42	0.17	0.93	0.93

^aThe mean expression of all studied genes has been compared between the defined subgroups

ISSN: 1471-2407